Clinical trials: Primary Progressive Aphasia
Dementia, Dementia Frontotemporal
Care Planning for a Loved One With Dementia: Knowledge, Preparing for Decisions, and Emotions
The overall objective of this study is to compare knowledge, decisional conflict, preferences, and caregiver burden over time caregivers of Alzheimer's Disease and Related Dementias (ADRD) patients by comparing the effectiveness…
- Conditions
- Dementia, Dementia Frontotemporal, Dementia Alzheimers, Dementia, Mild
- Trial name
- NCT05165186
- Testing
- Video Intervention Arm
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Niemann-Pick Disease, Type C
Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C
This study will evaluate clinical and laboratory tests that might be useful in determining if an investigational drug can slow the progression of Niemann-Pick Disease, Type C (NPC), a genetic disorder that results in progressive…
- Trial name
- NCT00344331
- Where
- United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Tauopathies, Neurodegenerative Diseases
Tau PET/CT in Various Tau-Related Disease Patients
To evaluate the potential usefulness of 18F-S16/T807 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.
- Conditions
- Tauopathies, Neurodegenerative Diseases, Neurodegeneration
- Trial name
- NCT06690983
- Testing
- 18F-S16/T807
- Where
- 3 sites in China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University
Dementia, Caregiver Burnout
WeCareAdvisor Study for Caregivers of People Living With Dementia
The WeCareAdvisor is an online tool to help caregivers manage behavioral and psychological symptoms of people living with dementia.
- Conditions
- Dementia, Caregiver Burnout, Caregiver Stress Syndrome, Alzheimer Disease
- Trial name
- NCT05012410
- Testing
- Immediate treatment group with High-Intensity Prompts, Immediate treatment group with Low-Intensity Prompts, Waitlist Control after three months with High-Intensity Prompts
- Where
- United States
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- Drexel University
Alzheimer's Disease, Frontotemporal Dementia
Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.
Study 18F-AV-45-010 is designed to evaluate the cerebral uptake of florbetapir 18F as measured by PET imaging in frontotemporal disorder (FTD) in comparison to cognitively normal volunteers and subjects with Alzheimer's disease…
- Trial name
- NCT01890343
- Testing
- florbetapir 18F, 18F-FDG
- Where
- United Kingdom
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Huntington's Disease (HD)
Biology-Driven Cognitive Profiling in Huntington's Disease
Huntington's disease (HD) is a genetic, progressive neurodegenerative disorder characterized by early and widespread brain changes that can begin more than a decade before the onset of unequivocal motor signs.
- Trial name
- NCT07503743
- Where
- Spain
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Frontotemporal Dementia, Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD) is a rare clinical entity, in which both disorders are variably associated in the same patient or within the family.
- Trial name
- NCT00159198
- Where
- 15 sites in France
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Alzheimer Disease, Dementia
DC Longitudinal Study on Aging and Specimen Bank
The Georgetown University Memory Disorders Program, part of the Department of Neurology, is conducting pilot studies of the feasibility of various diagnostic tests for Alzheimer's disease, mild cognitive impairment and other…
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment, Aging
- Trial name
- (DC LSOA) (NCT03702907)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Georgetown University
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Alzheimer's Disease Neuroimaging Initiative 2
The purpose of this study is to build upon the information obtained in the original Alzheimer's Disease Neuroimaging Initiative (ADNI1) and ADNI-GO (Grand Opportunity; a study funded through an NIH grant under the American…
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), Significant Memory Concern (SMC), Early Mild Cognitive Impairment (EMCI)
- Trial name
- ADNI2 (NCT01231971)
- Testing
- Florbetapir, Flortaucipir
- Where
- 58 sites in United States, Canada
- Volunteers
- 1,182 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Frontotemporal Dementia, Behavioral Variant, Alzheimer Disease
ECOCAPTURE for the Assessment of Apathy Under Real-life Conditions
ECOCAPTURE@HOME is a study which is currently being developed with the objective to capture the behavioral signature of apathy in everyday life context through remote monitoring of participants' behavior for about one month.
- Trial name
- @HOME (NCT04865172)
- Testing
- Remote collection of passive and active data for 28 consecutive days
- Where
- France
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Dementia, Mild Cognitive Impairment (MCI)
Comprehensive Assessment of Neurodegeneration and Dementia
This is a longitudinal observational study recruiting individuals between the ages of 50 and 90 with different types of dementia as well as a comparison group without cognitive deficits.
- Conditions
- Dementia, Mild Cognitive Impairment (MCI), Subjective Cognitive Impairment, Parkinson's Disease (PD)
- Trial name
- COMPASS-ND (NCT03402919)
- Where
- 19 sites in Canada
- Volunteers
- 1,573 people, healthy volunteers welcome
- Sponsor
- McGill University
Alzheimer's Disease
Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly
Alzheimer's disease (AD) is characterized by neuritic plaques, neurofibrillary tangles, and neuronal cell loss. Amyloid plaques are believed to play an integral role in AD.
- Trial name
- 11C-PIB PET (NCT00811122)
- Testing
- 11C-PIB PET Scan, FDG-PET Scan
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- University of Utah
Alzheimer's Disease, Brain Diseases
CNS Tau Kinetics in Healthy Aging and Alzheimer's Disease
Alzheimer's disease (AD) is the most common cause of dementia and currently has no disease modifying treatments or simple accurate diagnostic tests.
- Conditions
- Alzheimer's Disease, Brain Diseases, Central Nervous System Diseases, Delirium, Dementia, Amnestic, Cognitive Disorders
- Trial name
- NCT03938870
- Testing
- L-Leucine 13C6
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Tau Distributions in Patients With Tauopathy Using APN-1607 PET Scan
Establishing 18F PMPBB3 (APN 1607) PET Imaging Markers for Diagnosis of Tauopathy Parkinsonism Syndromes
Parkinson's disease (PD) is one of the most common neurodegenerative disorders. The diagnosis of PD is primarily based on clinical presentations while the pathology stage of a-synuclein containing Lewy body deposition has already…
- Trial name
- NCT04557865
- Testing
- 18F-PMPBB3 (APN-1607) PET imaging
- Where
- Taiwan
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Alzheimer Disease
Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease
The purpose of this study is to determine how inflammation is related to other changes in the brain that occur during the progression of Alzheimer's disease.
- Trial name
- ADVISe (NCT04576793)
- Testing
- 11C-ER176, 18F-MK6240, 18F-Florbetaben
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Columbia University
Alzheimer's Disease, Dementia With Lewy Bodies
Imaging of Brain Amyloid Plaques in the Aging Population
This is a prospective, open label, non-therapeutic, diagnostic imaging study. The purpose of this study is to utilize Pittsburgh Compound B positron emission imaging (PiB PET) to ascertain the relationship between change in…
- Conditions
- Alzheimer's Disease, Dementia With Lewy Bodies, Frontotemporal Dementia, Vascular Dementia
- Trial name
- NCT00950430
- Testing
- Pittsburgh Compound B (C-11 PiB), F-18 FDG, Tau (18-F-AV-1451)
- Where
- United States
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Aphasia, Primary Progressive, Repetitive Transcranical Magnetic Stimulation
rTMS for the Treatment of Primary Progressive Aphasia: A Randomized Controlled Trial
The primary progressive aphasia (PPA) is a neurodegenerative condition characterized by a gradual, irreversible decline of language function (Mesulam, 2001). There are no known treatments for PPA so far.
- Trial name
- NCT03448133
- Testing
- Magstim rTMS
- Volunteers
- healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Primary Progressive Aphasia, Nonfluent Progressive Aphasia
Language Treatment for Progressive Aphasia
Progressive aphasia is characterized by a steady and progressive loss of language skills in the presence of relatively preserved memory, attention, and thinking.
- Conditions
- Primary Progressive Aphasia, Nonfluent Progressive Aphasia, Semantic Dementia
- Trial name
- NCT00957710
- Testing
- Errorless learning
- Where
- Canada
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Baycrest
Alzheimer Disease
A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's Disease
This is a study to evaluate biodistribution, pharmacokinetics and safety of [18F]THK-5351 positron emission computed tomography in Cognitively Healthy Subjects and Patients with Alzheimer's Disease.
- Trial name
- NCT03112096
- Testing
- [18F]THK-5351
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Asan Foundation
Alzheimer Disease, Primary Progressive Aphasia
Identification of Graphic Markers of Neurocognitive Disorders (MG)
The diagnosis of neurocognitive disorders such as early Alzheimer's disease (AD) or primary progressive aphasia (PPA) is particularly difficult and constantly evolving, often leading to diagnostic erraticity.
- Conditions
- Alzheimer Disease, Primary Progressive Aphasia, Neurocognitive Disorders
- Trial name
- MG (NCT05537688)
- Testing
- Identification of Graphic Markers
- Where
- Canada
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal